OAE出版公司
期刊
会议
图书
作者:Alba Castán , Ylenia Navarro , Luis Sarría ...
来源:[J].Hepatoma Research, 2017, Vol.3 (1)OAE
摘要:Hepatocellular carcinoma (HCC) arising in non-cirrhotic livers is relatively rare. Compared with HCC arising in cirrhotic livers they have some quirks. HCC in healthy livers are large tumors at diagnosis, and are detected due to the onset of abdominal symptoms, outside of any sch...
作者:Oscar Briz , Maria J. Perez , Jose J. G. Marin
来源:[J].Hepatoma Research, 2017, Vol.3 (1)OAE
摘要:An important limitation for the success of chemotherapy in the treatment of primary liver cancer (hepatocellular carcinoma, hepatoblastoma and cholangiocarcinoma) is the marked efficacy of mechanisms of chemoresistance (MOC). These have been previously classified into five groups...
作者:Naganathan Selvakumar , Sandeep Vohra , Deep Sika Arora ...
来源:[J].Hepatoma Research, 2017, Vol.3 (1)OAE
摘要:Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the incidence is higher in cirrhosis. Treatment options depend on tumor stage, status of liver function, and the general condition of the patient. Major vascular invasion is a contraindication for li...
作者:Hanaa A. Hassan , Nermin E. Ghareb , Ghassan F. Azhari
来源:[J].Hepatoma Research, 2017, Vol.3 (2)OAE
摘要:Aim: Oxidative damage of cellular components by free radicals and other reactive oxygen molecules is believed to be associated with the development of degenerative diseases. The aim of the present study was to evaluate the antioxidant capacity and free radical scavenging activity...
作者:Lívia Maria Della Porta , Fernando Silva Ramalho , Carlos Augusto Oliveira ...
来源:[J].Hepatoma Research, 2017, Vol.3 (2)OAE
摘要:Aim: To investigate the correlation of p53 and prohibitin (PHB) expression in the spectrum of hepatitis, cirrhosis, and human hepatocellular carcinoma (HCC). Methods: Hepatic biopsies from patients with HCC (n = 60), cirrhosis (CIR, n = 30), hepatitis C virus (HCV, n = 30), ...
作者:Chien-Fu Hung , Dong Liu , Tsung-Han Wu ...
来源:[J].Hepatoma Research, 2017, Vol.3 (3)OAE
摘要:Aim: Sorafenib is a multi-tyrosine kinase inhibitor and the standard therapy for advanced hepatocellular carcinoma (HCC). This retrospective study aimed to observe the anti-fibrotic effect of sorafenib in patients with advanced HCC. Methods: Seventeen patients with advanced HCC w...
作者:Lynn G. Feun , Ying-Ying Li , Medhi Wangpaichitr ...
来源:[J].Hepatoma Research, 2017, Vol.3 (3)OAE
摘要:Systemic therapy for hepatocellular carcinoma (HCC) has been disappointing. The only drug approved by Food and Drug Administration recently has been sorafenib. Sorafenib has modest benefits with a low response rate and an improvement in time to progression of only 2-3 months. Mul...
作者:Chung Yeung Cheung , Kenneth S.H. Chok
来源:[J].Hepatoma Research, 2017, Vol.3 (4)OAE
摘要:Hepatorenal syndrome is not an uncommon life-threatening complication arising from liver cirrhosis. The diagnostic criteria for this syndrome have been revised throughout the years, with recent revisions aimed at improving earlier diagnosis and treatment. Liver transplantation re...
作者:Julia A. Zhang , Sandi A. Kwee , Linda L. Wong
来源:[J].Hepatoma Research, 2017, Vol.3 (4)OAE
摘要:Aim: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and liver transplant (LT) prolongs survival. However, 15-20% will experience recurrent HCC, most occurring within 2 years of LT. HCC patients with late recurrences (> 5 years after LT) ...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×